Heart Valve Disease Clinical Trial
Official title:
Prospective Randomized On-X Anticoagulation Clinical Trial (PROACT)
Various patient groups with the On-X Valve can be maintained safely on lower doses of blood thinner(Coumadin®) or on antiplatelet drugs (aspirin/Plavix®) only rather than the standard dose of Coumadin and aspirin presently recommended by ACC/AHA or ACCP professional societies.
This is a longitudinal, randomized (randomization to occur at the 3-month follow-up) study comparing the On-X valve on low dose anticoagulation (test group) to concomitant control groups of On-X valves receiving standard Coumadin/aspirin therapy, and also to FDA objective performance criteria (OPC) for heart valve replacement. It is a multicenter study consisting of up to 50 centers in the United States, Canada, and Italy enrolling and randomizing no more than 1200 patients (200 in each of 6 groups). There are three test arms of the study: low risk aortic valve replacement, high risk aortic valve replacement, and mitral valve replacement. Each arm has an equivalent control. Test therapies are: low risk aortic valve replacement - aspirin/Plavix, high risk aortic valve replacement - Coumadin at INR of 1.5 to 2.0 plus aspirin, and mitral valve replacement - Coumadin at an INR of 2.0 to 2.5 plus aspirin. Follow-up will run for up to 8 years in each patient. Each arm is independent and the low risk aortic and high risk aortic arms are completed. The low risk aortic arm was closed early resulting in a reduction of the estimated total enrollment with randomization to 1000. The high risk arm is completed with FDA review and this arm had 375 randomized enrollees. The mitral arm continues to enroll with a planned randomized enrollment of 400. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06027788 -
CTSN Embolic Protection Trial
|
N/A | |
| Completed |
NCT02527629 -
Aortic Replacement Using Individualised Regenerative Allografts - ARISE (the "Surveillance")
|
||
| Completed |
NCT01178710 -
Effect of Simvastatin on Cardiac Function
|
N/A | |
| Completed |
NCT01426776 -
Effect of Heart Valve Replacement on Cheyne-Stokes Respiration
|
N/A | |
| Completed |
NCT00581399 -
A Randomized Multicenter Clinical Study On the High Vacuum Body Cavity Drainage System Following Open Heart Surgery
|
Phase 2 | |
| Withdrawn |
NCT00187304 -
ACTION - Anticoagulation Treatment Influence on Post-operative Patients
|
Phase 4 | |
| Terminated |
NCT00700947 -
Using Beta Blockers to Treat Mitral Regurgitation
|
Phase 1 | |
| Recruiting |
NCT02574650 -
Early Feasibility of the Mitralign Percutaneous Tricuspid Valve Annuloplasty System (PTVAS) Also Known as TriAlign™.
|
N/A | |
| Recruiting |
NCT02650388 -
Frailty and Cognitive Function Assessment of TAVI Patients
|
Phase 4 | |
| Completed |
NCT01996657 -
D-dimer and Oral Anticoagulation Therapy in Patients With Mechanical Valve Replacement
|
N/A | |
| Terminated |
NCT00598936 -
A Prospective Study With a New Device for the Monitoring of Cerebral Oxygenation on Cardiac Surgery Patients
|
Phase 1 | |
| Terminated |
NCT01812174 -
On-X Heart Valve - 17mm Aortic and 23mm Mitral
|
N/A | |
| Recruiting |
NCT03225612 -
Safety and Performance of the Trialign Percutaneous Tricuspid Valve Annuloplasty System (PTVAS)
|
N/A | |
| Completed |
NCT01384643 -
Effect of Propofol on Renal Injury in Patients Undergoing Valvular Heart Surgery
|
Phase 4 | |
| Completed |
NCT01558765 -
CopenHeartVR - Integrated Rehabilitation of Patients After Heart Valve Surgery
|
Phase 2 | |
| Completed |
NCT02867930 -
Comparative Effects of Dexmedetomidine and Ketofol for Sedation in Patients Undergoing Trans-esophageal Echocardiography
|
Phase 4 | |
| Recruiting |
NCT02478008 -
A Clinical Study of the CardiAQ™ TMVI System (Transapical DS)
|
N/A | |
| Completed |
NCT02790008 -
Magnetic Resonance Imaging and Fibrosis
|
||
| Completed |
NCT02587039 -
An Intervention to Reduce Delirium After Cardiac Surgery
|
N/A | |
| Recruiting |
NCT01855737 -
The Study of Warfarin Maintenance Dose in Chinese Patients
|
Phase 4 |